Abstract
A test based on the inhibition by antibodies of the trans-sialidase was used to analyze infection by Trypanosoma cruzi, the agent of Chagas' disease. Sera collected during the longitudinal follow-up of benznidazole-treated acutely and congenitally infected patients became negative for T. cruzi as determined by tests presently used to assess cure; however, the sera remained positive for T. cruzi by the trans-sialidase inhibition assay (TIA) up to 14 years after treatment. Therefore, TIA is a highly sensitive marker for previous T. cruzi infection.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Animals
-
Antibodies, Protozoan / blood*
-
Argentina
-
Brazil
-
Chagas Disease / congenital
-
Chagas Disease / drug therapy
-
Chagas Disease / immunology*
-
Child
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Fluorescent Antibody Technique, Indirect
-
Follow-Up Studies
-
Humans
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical
-
Longitudinal Studies
-
Neuraminidase / antagonists & inhibitors*
-
Nitroimidazoles / therapeutic use
-
Paraguay
-
Pregnancy
-
Pregnancy Complications, Parasitic
-
Reference Values
-
Time Factors
-
Trypanosoma cruzi / immunology
Substances
-
Antibodies, Protozoan
-
Nitroimidazoles
-
Neuraminidase
-
benzonidazole